Resource Summary Report

Generated by dkNET on Aug 19, 2026

InVivoPlus anti-mouse CTLA-4 (CD152)

RRID:AB_10950184
Type: Antibody

Proper Citation

Bio X Cell Cat# BE0131, RRID:AB_10950184

Antibody Information

URL: http://antibodyregistry.org/AB_10950184

Proper Citation: Bio X Cell Cat# BE0131, RRID:AB_10950184

Target Antigen: CTLA-4 (CD152)

Host Organism: syrian hamster

Clonality: monoclonal

Comments: Applications: in vivo CTLA-4 neutralization, in vitro CTLA-4 neutralization Consolidation on 12/2021: AB_10950184, AB_2894807.

Antibody Name: InVivoPlus anti-mouse CTLA-4 (CD152)

Description: This monoclonal targets CTLA-4 (CD152)

Target Organism: mouse

Clone ID: clone 9H10

Antibody ID: AB_10950184

Vendor: Bio X Cell

Catalog Number: BE0131

Alternative Catalog Numbers: BP0131-5MG, BP0131-100MG, BE0131-100MG, BP0131-50MG, BE0131-25MG, BE0131-1MG, BP0131-25MG, BE0131-5MG, BE0131-50MG

Record Creation Time: 20250820T061247+0000

Record Last Update: 20250820T233248+0000

Ratings and Alerts

No rating or validation information has been found for InVivoPlus anti-mouse CTLA-4 (CD152).

No alerts have been found for InVivoPlus anti-mouse CTLA-4 (CD152).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 72 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Agesta A, et al. (2026) The transcription factor Eomes drives a stemness program in CD4+ T cells that promotes anti-tumor immunity in response to immunotherapy. Immunity, 59(7), 1876.

McVey JC, et al. (2026) Sequential platinum and PARP Inhibition enhances PD1 immunotherapy efficacy in murine Brca2 mutated pancreatic cancer. Scientific reports, 16(1), 6808.

Bui TM, et al. (2026) Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression. Cancer cell, 44(6), 1179.

Djureinovic D, et al. (2026) CD40 agonism in renal cell carcinoma enhances immune checkpoint activity through myeloid cells. iScience, 29(7), 116527.

Napoleon JV, et al. (2026) A Folate Receptor ?-Targeted TLR7 Agonist Significantly Augments Checkpoint Inhibitor Potencies by Reprogramming Tumor-Associated Macrophages and Myeloid-Derived Suppressor Cells. Journal of medicinal chemistry, 69(5), 5901.

Vuong L, et al. (2026) Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma. Cancer cell, 44(7), 1477.

Zhang H, et al. (2026) Programmable iPSC-derived CAR-NK vesicles remodel the immune microenvironment and eradicate tumors. Cell reports. Medicine, 7(2), 102545.

Li M, et al. (2026) SAICAR Drives T Regulatory Cell Differentiation and FOXP3 Maintenance to Promote Immunotherapy Resistance. Cancer research, 86(9), 2218.

Okuuchi A, et al. (2026) Hyperthermia Combined with Anti-CTLA-4 Antibody Induces Tumor Microenvironment Remodeling Involving CD4+ T Cells in Local and Distant Antitumor Effects in a Murine Triple-Negative Breast Cancer. Cancers, 18(8).

Karakousi T, et al. (2026) IFN?-dependent metabolic reprogramming restrains an immature, pro-metastatic lymphatic state in melanoma. Cancer cell, 44(4), 792.

Maru SY, et al. (2026) Antigen-presenting cancer-associated fibroblasts in murine pancreatic tumors differentially regulate T-cell phenotype and function. Journal of immunology (Baltimore, Md. : 1950), 215(6).

Blanchard L, et al. (2025) Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade. Cell reports. Medicine, 6(6), 102141.

Flem-Karlsen K, et al. (2025) Cytotoxic CD8+ T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity. Cancer research, 85(21), 4139.

Akca U, et al. (2025) PET Imaging of System A Amino Acid Transport Detects Early Response to Immune Checkpoint Inhibitor Therapy in a Syngeneic Mouse Model. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 66(12), 1908.

Cho NW, et al. (2025) T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNF? Inflammation. Cancer immunology research, 13(2), 229.

Lubrano S, et al. (2025) FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma. Cancer cell, 43(3), 428.

Gujar R, et al. (2025) Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. Cell reports. Medicine, 6(11), 102446.

Gong L, et al. (2025) Cancer immunology data engine reveals secreted AOAH as a potential immunotherapy. Cell, 188(18), 5062.

Bachem A, et al. (2025) Microbiota-derived butyrate promotes a FOXO1-induced stemness program and preserves CD8+ T cell immunity against melanoma. Immunity, 58(11), 2799.

von Locquenghien M, et al. (2025) Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy. Cell, 188(25), 7099.